Skip to content

Effect of a Food to Suppress the Increase in Postprandial Triglyceride Levels

Effect of a Food to Suppress the Increase in Postprandial Triglyceride Levels - Effect of a Food to Suppress the Increase in Postprandial Triglyceride Levels

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000035927
Enrollment
10
Registered
2019-02-19
Start date
2019-03-14
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N/A (healthy adults)

Interventions

[1]Oral ingestion of a test food (1 time). [2]Oral ingestion of a challenge diet. [3]Observation. [4]Washout (over 5 days). [5]No ingestion of a test food. [6]Oral ingestion of a challenge diet.

Sponsors

TES Holdings Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: [1]Japanese females aged 20-64 years. [2]Individuals who are healthy and are not suffered from a chronic malady including skin disease. [3]Individuals whose triglyceride level is normal or who are mild hyperlipemia (120mg/dL-199mg/dL). [4]Individuals whose written informed consent has been obtained. [5]Individuals who can visit an inspection facility and be inspected in designated days. [6]Individuals judged appropriate for the study by the principal.

Exclusion criteria

Exclusion criteria: [1]Individuals using medical products. [2]Individuals who are or are under treatment or have a history of hyperlipidemia, hypertension, diabetes, mental disabilities, sleep disorder or the other serious dysfunctions. [3]Individuals who used a drug to treat in the past 1 month (One-shot medicine of a headache, menstrual pain and a cold removes it). [4]Individuals who have a history of serious hepatopathy, kidney damage, heart disease, lung disease, or blood disease. [5]Individuals who have digestive organ disease (disease of an appendix is removed). [6]Individuals whose menstrual period is during the test period and with serious anemia or poor physical condition during the period. [7]Individuals whose BMI is over 30kg/m2. [8]Individuals who donated blood over 200mL in the past 1 month or over 400mL in the past 3 months. [9]Individuals with serious anemia. [10]Individuals who are sensitive to test products or causes severe allergy in a food and medical supplies. [11]Individuals who cannot intake every loading food or test food. [12]Individuals who are or are possibly pregnant, or are lactating. [13]Individuals who are based on average alcohol per 1 day and exceeds 60g/day. [14]Individuals whose life style will change during the test period (ex.travel for a long time). [15Individuals who had a habit to ingest health-promoting foods, foods for specified health uses, health foods, or supplements which adopt to improve lipid metabolism or glucose metabolism in the past 3 months or will ingest those foods during the test period. [16]Individuals who participated in other clinical studies in the past 3 months. [17]Individuals judged inappropriate for the study by the principal.

Design outcomes

Primary

MeasureTime frame
[1]Efficacy evaluation (changes, increase and decrease of TG, NEFA, lipoprotein fraction, RLP-C [before ingestion of a challenge diet, and 2, 3, 4, 6 hours after ingestion of a challenge diet; AUC and iAUC of TG, NEFA, lipoprotein fraction, RLP-C [observation period I and II]).

Secondary

MeasureTime frame
*Indexes for safety [1]Blood pressure, pulsation (screening and before ingestion of a challenge diet). [2]Weight, body fat percentage, BMI (screening and before ingestion of a challenge diet) . [3]Doctor's questions (screening, before ingestion of a challenge diet, and 6 hours after ingestion of a challenge diet). [4]Subject's diary (from one day before ingestion of a challenge diet in observation period I to one day before ingestion of a challenge diet in observation period II). *Other indexes [1]Hematologic test (screening). [2]Blood biochemical test (screening). [3]Urine analysis (screening).

Countries

Japan

Contacts

Public ContactRyoma Shimizu

TES Holdings Co., Ltd. Administrative Department of Clinical Trials

r.shimizu@tes-h.co.jp+81-3-6801-8480

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026